Celldex (CLDX) – Momentum Movers
-
Celldex (CLDX) Climbs 17% Following Positive Data from Barzolvolimab Phase 1b Study
-
Celldex (CLDX) RINTEGA Phase 3 ACT V Recommended for Continuation by IDSMB
-
-
-
-
-
-
-
Back to CLDX Stock Lookup